Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Marsh & McLennan Companies, Inc. (MRSH) vs Stryker Corporation (SYK) Price & Performance

Marsh & McLennan Companies, Inc.Trade
Stryker CorporationTrade

Price performance (Past 24H)

Key statistics

Marsh & McLennan Companies, Inc. vs Stryker Corporation — how do they compare? Marsh & McLennan Companies, Inc. trades at $175.71 (market cap $84.31B), while Stryker Corporation trades at $277.7 (market cap $106.24B). The key difference: Stryker Corporation is the larger of the two by market cap, and Marsh & McLennan Companies, Inc. pays the higher dividend (2.24%). Which is the better fit depends on your goals.

MRSHSYK
Market Cap
$84.31B$106.24B
Volume
3,948,9472,982,001
Sector
FinancialsHealth
52-Week High
$207.02$388.35
52-Week Low
$157.32$269.75
Enterprise Value
$104.99B$117.70B
Dividend Yield
2.24%1.27%
Typical Hold Time
—21 Days

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Marsh & McLennan Companies, Inc.

MRSH trades at $176.16, up 1.44% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company completed the acquisition of Accel Holdings on October 2, 2026, expanding its advisory footprint. Revenue grew to $27.0B in 2025, with a net income margin of 15.41%, while valuation ratios like P/E of 21.57 and ROE of 25.72% reflect strong profitability. Analysts maintain a consensus price target of $202.71, though sentiment is mixed with a 'Hold' rating from most.

The outlook for MRSH is positive due to earnings momentum and strategic acquisitions, but risks include competitive pressures and potential margin compression. Upside remains if the company meets Q3 2026 EPS expectations of $1.97, supported by solid cash flow trends. Investors should weigh the high P/B ratio of 5.55 against growth prospects in the reinsurance sector.

Stryker Corporation

Stryker (SYK) trades at $279.15, up 1.36% on the day, amid a mixed technical and fundamental backdrop. The stock shows bearish technical signals with key support at $268 and resistance at $284, while fundamentals remain solid with a 14.43% net income margin and strong analyst consensus of 71% buy ratings. Recent news highlights ongoing legal scrutiny over manufacturing issues, but the company maintains robust cash flow and earnings growth, with Q3 2026 results pending.

Outlook: SYK offers growth potential with a consensus price target of $368.11, supported by profitability and innovation, but faces near-term risks from legal investigations and technical weakness. Investors should weigh strong fundamentals against sentiment headwinds.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MRSH
100% Buy0% Sell
SYK

No sentiment data available yet.

Top news

Latest headlines on both assets

About Marsh & McLennan Companies, Inc.

Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).

Read more on MRSH →

About Stryker Corporation

Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.

Read more on SYK →